- CConnexion
RééDOC
75 Boulevard Lobau 54042 NANCY cedex Christelle Grandidier Documentaliste 03 83 52 67 64 0
|
Tolerability profiles of rofecoxib (Vioxx (R)) and Arthrotoc (R) - A comparison of six weeks treatment in patients with osteoarthritis
ACEVEDO E; CASTANEDA O; UGAZ M
SCAND J RHEUMATOL , 2001, vol. 30, n° 1, p. 19-24 Doc n°: 99428 Localisation : Documentation IRR Descripteurs : DA52 - MALADIES RHUMATISMALES OBJECTIVE: To compare the incidence of selected spontaneously reported adverse events (AEs) in patients with osteoarthritis (OA) treated with rofecoxib (VIOXX, 12.5 mg qd) or Arthrotec (diclofenac 50 mg/misoprostol 200 mcg bid). METHODS: Double-blind, parallel-group, 6-week study of patients aged > or = 40 years with a clinical diagnosis of OA treated with rofecoxib or Arthrotec. Primary endpoint: self-reported diarrhea; secondary endpoints: abdominal pain, discontinuations due to AEs, GI AEs and NSAID-type GI AEs (ie., acid reflux, dyspepsia, epigastric discomfort, heartburn, nausea, vomiting). RESULTS: Among 483 patients (80.3% females, mean age 62.1), the rofecoxib group vs the Arthrotec group respectively reported diarrhea 6.2% vs 16.2% (p<0.001); drug-related diarrhea 3.7% vs 16.2% (p<0.001); one or more clinical AEs 52.9% vs 73.0% (p<0.001); GI AEs 28.9% vs 48.5% (p<0.001); NSAID-type GI AEs 18.6% vs 29.9% (p=0.004); discontinuations due to abdominal pain 0.4% vs 3.7% (p<0.05); and discontinuations due to any AE 4.1% vs 9.1% (p=0.029). No significant differences were observed in efficacy. CONCLUSION: Rofecoxib 12.5 mg qd has improved GI tolerability and similar efficacy compared to Arthrotec (diclofenac 50 mg/misoprostol 200 mcg bid). Langue : ANGLAIS Tiré à part : OUI Identifiant basis : 2001215364 |
0
|